Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MLN4924 + itraconazole is an investigational combination used in clinical pharmacokinetic studies to evaluate drug-drug interactions. MLN4924 (also known as pevonedistat or TAK-924) is a **small molecule inhibitor of the NEDD8-activating enzyme (NAE)**, which suppresses cullin-RING ligase (CRL) activity and disrupts proteasomal protein degradation in malignant cells, leading to cell cycle arrest and apoptosis. *Itraconazole* is an antifungal agent and a strong inhibitor of CYP3A and P-glycoprotein (P-gp), used in the combination to assess its impact on MLN4924 metabolism. The combination is not a marketed therapy but was studied for drug-drug interactions and safety in patients with advanced solid tumors[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MLN4924 + itraconazole.